Recombinant COVID-19 vaccine (CHO cell)

BIOLOGICAL3 trials

Sponsors

National Vaccine and Serum Institute, China, Guangzhou Patronus Biotech Co., Ltd., WestVac Biopharma Co., Ltd.

Conditions

COVID-19COVID-19 PneumoniaCoronavirus Infections

Phase 1

Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above

Guangzhou Patronus Biotech Co., Ltd.COVID-19

Start: 2022-07-19End: 2023-12-01Updated: 2023-03-10

Phase 2

Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above

National Vaccine and Serum Institute, ChinaCoronavirus Infections, COVID-19 Pneumonia

Start: 2021-09-12End: 2024-01-31Updated: 2023-02-02

Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)

CompletedNCT05770180

WestVac Biopharma Co., Ltd.COVID-19

Start: 2023-03-30End: 2024-04-09Updated: 2024-07-24

Related Papers

Safety and immunogenicity of the SARS-CoV-2 LYB001 RBD-based VLP vaccine (CHO cell) phase 1 in Chinese adults: a randomized, double-blind, positive-parallel-controlled study

Expert Review of Vaccines2024-05-027 citations